Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29758112 | 1.00 | KMT2A (0.63) | KMT2AHSD17B10KDM4EALDH1A1HTT | |
| SCHEMBL2193401 | 0.85 | KMT2A (0.47) | KMT2AHSD17B10KDM4EALDH1A1HTT | |
| SCHEMBL2699875 | 0.82 | P2RX7 (0.46) | KMT2AHSD17B10KDM4ESMN1; SMN2HPGD | |
| SCHEMBL1196908 | 0.81 | KMT2A (0.45) | KMT2AHSD17B10KDM4EALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL1016467 | 0.80 | KMT2A (0.44) | KMT2AHSD17B10KDM4EALDH1A1HTT | |
| SCHEMBL16574014 | 0.79 | HSD17B10 (0.54) | KMT2AHSD17B10ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1016531 | 0.78 | SMN1; SMN2 (0.42) | KMT2AHSD17B10KDM4EALDH1A1LMNA | |
| SCHEMBL23466602 | 0.77 | SMN1; SMN2 (0.67) | KMT2AKDM4EALDH1A1HTTLMNA | |
| SCHEMBL29758010 | 0.77 | SMN1; SMN2 (0.67) | KMT2AKDM4EALDH1A1HTTLMNA | |
| SCHEMBL30168172 | 0.77 | ALDH1A1 (0.57) | KMT2AHSD17B10KDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114728917-B | Oxamide derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-114728917-A | Oxamide derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021110076-A1 | OXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 深圳信立泰药业股份有限公司 | 2021-06-10 | — | — | WO | disclosed |
| WO-2021110076-A1 | OXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 深圳信立泰药业股份有限公司 | 2021-06-10 | — | — | WO | disclosed |
| US-8344028-B2 | Gamma-amino-butyric acid derivatives as GABAB receptor ligands | XENOPORT, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2419401-A2 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAb RECEPTOR LIGANDS | XenoPort, Inc. (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20120035139-A9 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | XENOPORT, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20100267676-A1 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | XENOPORT, INC. | 2010-10-21 | — | — | US | disclosed |
| WO-2010120370-A2 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | XENOPORT, INC. (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267676-A1 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | GABRB2, GABRB1, GABRB3 | KMT2A 3550/4885HSD17B10 1005/4885KDM4E 3716/4885 |
| US-20120035139-A9 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | GABRB2, GABRB1, GABRB3 | KMT2A 3550/4885HSD17B10 1005/4885KDM4E 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.